Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.
Plummer, Ruth; Jones, Christopher; Middleton, Mark; Wilson, Richard; Evans, Jeffrey; Olsen, Anna; Curtin, Nicola; Boddy, Alan; McHugh, Peter; Newell, David; Harris, Adrian; Johnson, Patrick; Steinfeldt, Heidi; Dewji, Raz; Wang, Diane; Robson, Lesley; Calvert, Hilary.
Clin Cancer Res
; 14(23): 7917-23, 2008 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-19047122
Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.
Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Temozolomide analogs with improved brain/plasma ratios - Exploring the possibility of enhancing the therapeutic index of temozolomide.
Ghee Butter as a Therapeutic Delivery System.
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma.
Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model.
Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?
The simulation of UV spectroscopy and electronic analysis of temozolomide and dacarbazine chemical decomposition to their metabolites.
Formulation and statistical optimization of intravenous temozolomide-loaded PEGylated liposomes to treat glioblastoma multiforme by three-level factorial design.